RCUS
RCUS
NYSE · Biotechnology

Arcus Biosciences Inc

$21.64
-0.79 (-3.52%)
As of Mar 22, 10:01 PM ET ·
Financial Highlights (FY 2026)
Revenue
328.18M
Net Income
-359,987,575
Gross Margin
Profit Margin
-109.7%
Rev Growth
-12.3%
D/E Ratio
0.10
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 44.4% 44.4%
Operating Margin -127.9% -115.1% -6.5% -6.4%
Profit Margin -109.7% -104.2% -8.0% -7.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 328.18M 374.34M 841.86M 875.48M
Gross Profit 374.19M 389.13M
Operating Income -419,779,534 -430,935,987 -54,514,708 -55,744,444
Net Income -359,987,575 -369,554,941 -67,570,170 -63,346,573
Gross Margin 44.4% 44.4%
Operating Margin -127.9% -115.1% -6.5% -6.4%
Profit Margin -109.7% -104.2% -8.0% -7.2%
Rev Growth -12.3% -12.3% +8.2% -1.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 108.56M 108.56M 401.69M 484.63M
Total Equity 1.10B 1.10B 1.67B 1.64B
D/E Ratio 0.10 0.10 0.24 0.30
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -412,134,772 -446,592,943 -58,220,570 -69,808,840
Free Cash Flow -41,442,789 -42,253,468